FIG 1.

Long-term PFS with selpercatinib​. Kaplan-Meier plots show PFS for the (A) RET-mutant MTC cabozantinib/vandetanib-naïve group, (B) RET-mutant MTC pretreated group, (C) RET fusion-positive TC treatment-naïve group, and (D) RET fusion-positive TC pretreated group. Tick marks indicate censored data. Eligible patients are defined as treated patients. Patients enrolled in phase II who discontinued selective RET inhibitor(s) because of intolerance were excluded. MTC, medullary thyroid cancer; PFS, progression-free survival; RET, REarranged during Transfection; TC, thyroid cancer.